September 23, 2024
The Federal Circuit has backed a Patent Trial and Appeal Board finding that more than two dozen claims in a Novartis pre-filled eye injection syringe patent weren't patentable.
January 25, 2023
The Patent Trial and Appeal Board has found that more than two dozen claims in a Novartis pre-filled eye injection syringe patent weren't patentable, handing Regeneron a win in a larger legal fight between the parties.
July 21, 2022
The Patent Trial and Appeal Board on Thursday considered whether Novartis can beat an invalidity challenge from Regeneron over a pre-filled eye injection syringe patent with an argument that skilled artisans would not have come up with the invention because of safety concerns.
October 27, 2021
Regeneron has convinced the Patent Trial and Appeal Board to review claims in a Novartis patent that covers a type of syringe used in eye injections after the Swiss drug giant dropped a related case against Regeneron at the U.S. International Trade Commission.